Skip to content

Behrman Capital Invests in Emmes

New York, March 11, 2019 – Behrman Capital (“Behrman”), a private equity investment firm based in New York and San Francisco, today announced that it has made a significant investment in The Emmes Corporation (“Emmes” or “the Company”). Financial terms of the transaction were not disclosed.

Emmes is a leading contract research organization (“CRO”) that partners with government, private foundation, and commercial clients to develop treatments for diseases and disorders impacting public health. The Company has provided clinical trial services for over 1,000 trials across Phase I-IV in more than 70 countries, and has a particular expertise in biostatistics, offering government and commercial customers unique capabilities in the analysis and management of clinical trial data.

Behrman is investing in Emmes in partnership with members of the company’s senior management team, which will continue to lead the Company, as well as Sal Guccione, the former CEO of WIL Research (a previous Behrman portfolio company), who has joined Emmes as Executive Chairman.

Grant G. Behrman, Managing Partner of Behrman Capital, said, “Emmes has built a strong and enduring heritage as a trusted and collaborative research partner. The Company is well positioned for growth in the near- and long-term, across a number of therapeutic areas of focus including infectious disease, oncology and ophthalmology. We look forward to partnering with Anne, Sal, and Emmes’ world-class team to increase the scope and scale of the business through organic initiatives and accretive acquisitions.”

“This is a substantial and exciting milestone in our evolution,” said Dr. Anne Lindblad, President and Chief Executive Officer of Emmes. “Our vision, mission, leadership, and focus on advancing human health will continue, and we will benefit from Behrman’s investment, expertise and relationships. We believe this investment will allow us to provide employees even greater opportunities as we continue to build and grow. Our government work is and will remain core, and we plan to accelerate our efforts on the non-government side. In addition, Behrman will be a great resource in expanding our global presence, sharing market research that can shape new business opportunities, and identifying key hires that would complement our existing team.”

Mr. Guccione added, “I am delighted to join Emmes and to have another opportunity to partner with Behrman Capital. Emmes has a longstanding reputation of working side-by-side with leading researchers to tackle the world’s greatest public health challenges. I look forward to collaborating with Anne and the management team to expand and strengthen Emmes’ service offerings and international presence.”

About Behrman Capital

Based in New York City and San Francisco, Behrman Capital was founded in 1991 by Grant G. and Darryl G. Behrman. The firm invests in management buyouts, leveraged buildups and recapitalizations of established growth businesses. The company’s investments are focused in three industries: defense and aerospace, healthcare services, and specialty manufacturing and distribution. The firm has raised in excess of $3.0 billion since inception and is currently investing out of its sixth fundFor more information, please visit

About Emmes

We collaborate with our clients to produce valued, trusted scientific research. Our team members at Emmes are passionate about making a difference in the quality of human health, and we have supported more than a thousand studies across a diverse range of diseases since our formation in 1977. Our research is contributing to a healthier world. For more information, visit the Emmes website at


Mark Semer or Daniel Hoadley
Kekst CNC
(212) 521-4800 /

Back To Top